Compass Pathways Schedules Webinar on Psilocybin Therapy Advances for Depression and PTSD

LONDON – Compass Pathways plans to hold a virtual webinar to outline its steps toward launching a psilocybin-based therapy for treatment-resistant depression (TRD) and to share details on upcoming trials for post-traumatic stress disorder (PTSD).

The session will feature discussions from medical experts and industry executives on current challenges in treating these conditions, including care delivery models and economic factors for providers. Participants include:

• Gary Small, MD, Chair of Psychiatry at Hackensack University Medical Center,
• Geoff Grammer, MD, CMO at Greenbrook Mental Wellness Centers,
• Myriam Barthes, co-founder and CEO at Journey Clinical, and
• Dimitri Cavathas, CEO at HealthPort.

Compass Pathways’ lead candidate, COMP360, a synthetic form of psilocybin, received breakthrough therapy designation from the U.S. Food and Drug Administration last year, speeding its path toward potential approval for TRD. In June, the company reported positive top-line results from its first Phase 3 trial, showing sustained symptom relief at six weeks compared with a placebo. This builds on earlier data from a Phase 2b study published in the New England Journal of Medicine, which demonstrated rapid and durable effects in patients who had not responded to standard antidepressants.

The webinar comes after Compass Pathways accelerated its commercial timeline by nine to twelve months in its Q3 earnings report last fall, signaling confidence in scaling operations for a possible 2027 market entry. Analysts note this positions the company ahead of rivals in the psychedelics space, where regulatory hurdles and reimbursement questions remain key barriers. For instance, multi-hour therapy sessions required for psilocybin could strain clinic resources, but partnerships like those with Journey Clinical aim to standardize protocols and ease adoption.

On the PTSD front, Compass Pathways intends to reveal plans for a late-stage trial of COMP360, targeting a patient group that often cycles through ineffective therapies. Early evidence from investigator-led studies suggests psilocybin may reduce avoidance behaviors and hyperarousal, though larger trials will test durability against benchmarks like prolonged exposure therapy.

As the psychedelics sector matures, events like this one offer a window into how firms are bridging clinical gains with practical rollout, a process that will define winners in addressing mental health gaps. Along with that, this development underscores the steady progress in evidence-driven therapies, where measured execution could unlock substantial value for investors tracking the intersection of biotech and behavioral health.